Table 3.
Associations between the SLC6A3 rs3836790 genotype (Int8 VNTR) and changes in the severity of gait disorders during l-DOPA treatment
|
SLC6A3 |
||||
|---|---|---|---|---|
| Parameter | Condition | 5/5 or 5/6 (n = 28) | 6/6 (n = 33) | P*,† |
| Number of steps in the SWS | ||||
| OFF | 33 (28–53) | 34 (27–40) | ||
| ON | 34 (25–42) | 25 (20–28) | ||
| Difference (%) | 9.2 (–4.6–29.7) | 27.6 (17.2–34.3) | 0.001/<0.001 | |
| SWS completion time, s | ||||
| OFF | 23 (19–58) | 25 (18–34) | ||
| ON | 19 (15–33) | 15 (11–19) | ||
| Difference (%) | 10.2 (4.8–32.4) | 42.1 (18.9–56.6) | 0.002/0.001 | |
| Number of freezing of gait episodes during the freezing of gait trajectory | ||||
| OFF | 7 (5–12) | 6 (4–10) | ||
| ON | 5 (2–10) | 2 (1–5) | ||
| Difference (%) | 11.8 (0.0–57.3) | 50.0 (25.0–83.3) | 0.005/0.005 | |
Data are reported as the median (interquartile range) values in the OFF and ON conditions and the difference between the two. *In a Wilcoxon test; †In a non-parametric covariance analysis adjusted for the dose of l-DOPA. SWS = Stand-Walk-Sit Test.